Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on October 20, 2016. The filing serves as a Regulation FD disclosure regarding a scientific presentation made by the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure event and does not contain financial statements or performance metrics.
Material Changes
There are no financial material changes reported in this document. The material event disclosed is the presentation of a research poster titled "reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound NSI-189" at the Radiation Research Society Annual Meeting on October 19, 2016.
Guidance, Outlook, and Risks
- Management Commentary: The Company announced the poster presentation regarding its compound NSI-189.
- Legal Disclaimer: The information in this Item 7.01 and the attached press release (Exhibit 99.01) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: No specific financial risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for detailed data on the NSI-189 study.
- Confirm the clinical significance of the "reversal of radiation-induced cognitive impairment" results presented at the Radiation Research Society Annual Meeting.
- Review subsequent filings for any financial impact or strategic shifts resulting from this scientific disclosure.